Gyre Therapeutics, Inc. Increase (Decrease) in Accrued Liabilities
Gyre Therapeutics, Inc. (GYRE) reported Increase (Decrease) in Accrued Liabilities of -$2.41 million for the 9-month period ending 2023-09-30, per its 10-Q filed 2023-10-26.
Discontinued › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccruedLiabilities · last filed 2023-10-26
- Gyre Therapeutics, Inc. increase (decrease) in accrued liabilities for the quarter ending 2023-09-30 was $337.00K.
- Gyre Therapeutics, Inc. increase (decrease) in accrued liabilities for the quarter ending 2023-06-30 was -$335.00K.
- Gyre Therapeutics, Inc. increase (decrease) in accrued liabilities for the quarter ending 2023-03-31 was -$2.41M, a 332.72% decline year-over-year.
- Gyre Therapeutics, Inc. increase (decrease) in accrued liabilities for the quarter ending 2022-12-31 was $2.42M.
- Gyre Therapeutics, Inc. increase (decrease) in accrued liabilities for fiscal 2022 was -$1.90M.
- Gyre Therapeutics, Inc. increase (decrease) in accrued liabilities for fiscal 2021 was -$3.68M, a 4587.80% decline from fiscal 2020.
- Gyre Therapeutics, Inc. increase (decrease) in accrued liabilities for fiscal 2020 was $82.00K, a 98.54% decline from fiscal 2019.
- Gyre Therapeutics, Inc. increase (decrease) in accrued liabilities for fiscal 2019 was $5.60M, a 558.71% increase from fiscal 2018.
| Period end | Increase (Decrease) in Accrued Liabilities 3 month | Increase (Decrease) in Accrued Liabilities 6 month | Increase (Decrease) in Accrued Liabilities 9 month | Increase (Decrease) in Accrued Liabilities 12 month | Increase (Decrease) in Accrued Liabilities 12 month as first filed |
|---|---|---|---|---|---|
| 2023-09-30 | $337.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-10-26 | $2.00K derived: sum of 2 quarters · filed 2023-10-26 | -$2.41M 10-Q · filed 2023-10-26 | $13.00K derived: sum of 4 quarters · filed 2023-10-26 | |
| 2023-06-30 | -$335.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-14 | -$2.75M 10-Q · filed 2023-08-14 | -$324.00K derived: sum of 3 quarters · filed 2023-08-14 | -$961.00K derived: sum of 4 quarters · filed 2023-10-26 | |
| 2023-03-31 | -$2.41M 10-Q · filed 2023-05-15 | $11.00K derived: sum of 2 quarters · filed 2023-05-15 | -$626.00K derived: sum of 3 quarters · filed 2023-10-26 | -$5.34M derived: sum of 4 quarters · filed 2023-10-26 | |
| 2022-12-31 | $2.42M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-30 | $1.78M derived: sum of 2 quarters · filed 2023-10-26 | -$2.93M derived: sum of 3 quarters · filed 2023-10-26 | -$1.90M 10-K · filed 2023-03-30 | |
| 2022-09-30 | -$637.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-10-26 | -$5.35M derived: sum of 2 quarters · filed 2023-10-26 | -$4.32M 10-Q · filed 2023-10-26 | -$9.47M derived: sum of 4 quarters · filed 2023-10-26 | |
| 2022-06-30 | -$4.72M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-14 | -$3.68M 10-Q · filed 2023-08-14 | -$8.83M derived: sum of 3 quarters · filed 2023-08-14 | -$8.02M derived: sum of 4 quarters · filed 2023-08-14 | |
| 2022-03-31 | $1.04M 10-Q · filed 2023-05-15 | -$4.12M derived: sum of 2 quarters · filed 2023-05-15 | -$3.31M derived: sum of 3 quarters · filed 2023-05-15 | -$2.61M derived: sum of 4 quarters · filed 2023-05-15 | |
| 2021-12-31 | -$5.15M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-30 | -$4.34M derived: sum of 2 quarters · filed 2023-03-30 | -$3.65M derived: sum of 3 quarters · filed 2023-03-30 | -$3.68M 10-K · filed 2023-03-30 | |
| 2021-09-30 | $810.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | $1.50M derived: sum of 2 quarters · filed 2022-11-14 | $1.47M 10-Q · filed 2022-11-14 | -$601.00K derived: sum of 4 quarters · filed 2022-11-14 | |
| 2021-06-30 | $694.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-15 | $663.00K 10-Q · filed 2022-08-15 | -$1.41M derived: sum of 3 quarters · filed 2022-08-15 | -$1.08M derived: sum of 4 quarters · filed 2022-08-15 | |
| 2021-03-31 | -$31.00K 10-Q · filed 2022-05-09 | -$2.10M derived: sum of 2 quarters · filed 2022-05-09 | -$1.77M derived: sum of 3 quarters · filed 2022-05-09 | -$815.00K derived: sum of 4 quarters · filed 2022-05-09 | |
| 2020-12-31 | -$2.07M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-31 | -$1.74M derived: sum of 2 quarters · filed 2022-03-31 | -$784.00K derived: sum of 3 quarters · filed 2022-03-31 | $82.00K 10-K · filed 2022-03-31 | |
| 2020-09-30 | $331.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-12 | $1.29M derived: sum of 2 quarters · filed 2021-11-12 | $2.16M 10-Q · filed 2021-11-12 | $4.81M derived: sum of 4 quarters · filed 2021-11-12 | |
| 2020-06-30 | $959.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-05 | $1.82M 10-Q · filed 2021-08-05 | $4.48M derived: sum of 3 quarters · filed 2021-08-05 | $5.62M derived: sum of 4 quarters · filed 2021-08-05 | |
| 2020-03-31 | $866.00K 10-Q · filed 2021-05-06 | $3.52M derived: sum of 2 quarters · filed 2021-05-06 | $4.66M derived: sum of 3 quarters · filed 2021-05-06 | $6.37M derived: sum of 4 quarters · filed 2021-05-06 | |
| 2019-12-31 | $2.65M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-04 | $3.80M derived: sum of 2 quarters · filed 2021-03-04 | $5.50M derived: sum of 3 quarters · filed 2021-03-04 | $5.60M 10-K · filed 2021-03-04 | |
| 2019-09-30 | $1.14M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-05 | $2.84M derived: sum of 2 quarters · filed 2020-11-05 | $2.94M 10-Q · filed 2020-11-05 | $3.56M derived: sum of 4 quarters · filed 2020-11-05 | |
| 2019-06-30 | $1.70M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-06 | $1.80M 10-Q · filed 2020-08-06 | $2.42M derived: sum of 3 quarters · filed 2020-08-06 | $3.05M derived: sum of 4 quarters · filed 2020-08-06 | |
| 2019-03-31 | $100.00K 10-Q · filed 2020-05-11 | $716.00K derived: sum of 2 quarters · filed 2020-05-11 | $1.34M derived: sum of 3 quarters · filed 2020-05-11 | $2.17M derived: sum of 4 quarters · filed 2020-05-11 | |
| 2018-12-31 | $616.00K derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-20 | $1.24M derived: sum of 2 quarters · filed 2020-02-20 | $2.08M derived: sum of 3 quarters · filed 2020-02-20 | $850.00K 10-K · filed 2020-02-20 | |
| 2018-09-30 | $627.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-07 | $1.46M derived: sum of 2 quarters · filed 2019-11-07 | $234.00K 10-Q · filed 2019-11-07 | $907.00K derived: sum of 4 quarters · filed 2019-11-07 | |
| 2018-06-30 | $832.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-01 | -$393.00K 10-Q · filed 2019-08-01 | $280.00K derived: sum of 3 quarters · filed 2019-08-01 | $160.00K derived: sum of 4 quarters · filed 2019-08-01 | |
| 2018-03-31 | -$1.23M 10-Q · filed 2019-05-02 | -$552.00K derived: sum of 2 quarters · filed 2019-05-02 | -$672.00K derived: sum of 3 quarters · filed 2019-05-02 | $88.00K derived: sum of 4 quarters · filed 2019-05-02 | |
| 2017-12-31 | $673.00K derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-08 | $553.00K derived: sum of 2 quarters · filed 2019-03-08 | $1.31M derived: sum of 3 quarters · filed 2019-03-08 | $1.29M 10-K · filed 2019-03-08 | |
| 2017-09-30 | -$120.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-01 | $640.00K derived: sum of 2 quarters · filed 2018-11-01 | $614.00K 10-Q · filed 2018-11-01 | $681.00K derived: sum of 4 quarters · filed 2018-11-01 | |
| 2017-06-30 | $760.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-02 | $734.00K 10-Q · filed 2018-08-02 | $801.00K derived: sum of 3 quarters · filed 2018-08-02 | $997.00K derived: sum of 4 quarters · filed 2018-08-02 | |
| 2017-03-31 | -$26.00K 10-Q · filed 2018-05-03 | $41.00K derived: sum of 2 quarters · filed 2018-05-03 | $237.00K derived: sum of 3 quarters · filed 2018-05-03 | $355.00K derived: sum of 4 quarters · filed 2018-05-03 | |
| 2016-12-31 | $67.00K derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-19 | $263.00K derived: sum of 2 quarters · filed 2018-03-19 | $381.00K derived: sum of 3 quarters · filed 2018-03-19 | -$60.00K 10-K · filed 2018-03-19 | |
| 2016-09-30 | $196.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-02 | $314.00K derived: sum of 2 quarters · filed 2017-11-02 | -$127.00K 10-Q · filed 2017-11-02 | -$6.00K derived: sum of 4 quarters · filed 2017-11-02 | |
| 2016-06-30 | $118.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-03 | -$323.00K 10-Q · filed 2017-08-03 | -$202.00K derived: sum of 3 quarters · filed 2017-08-03 | $323.00K derived: sum of 4 quarters · filed 2017-08-03 | |
| 2016-03-31 | -$441.00K 10-Q · filed 2017-05-11 | -$320.00K derived: sum of 2 quarters · filed 2017-05-11 | $205.00K derived: sum of 3 quarters · filed 2017-05-11 | $246.00K derived: sum of 4 quarters · filed 2017-05-11 | |
| 2015-12-31 | $121.00K derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-08 | $646.00K derived: sum of 2 quarters · filed 2017-03-08 | $687.00K derived: sum of 3 quarters · filed 2017-03-08 | $1.15M 10-K · filed 2017-03-08 | |
| 2015-09-30 | $525.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-03 | $566.00K derived: sum of 2 quarters · filed 2016-11-03 | $1.03M 10-Q · filed 2016-11-03 | $1.06M derived: sum of 4 quarters · filed 2016-11-03 | |
| 2015-06-30 | $41.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-04 | $504.00K 10-Q · filed 2016-08-04 | $540.00K derived: sum of 3 quarters · filed 2016-08-04 | $485.00K derived: sum of 4 quarters · filed 2016-08-04 | |
| 2015-03-31 | $463.00K 10-Q · filed 2016-05-05 | $499.00K derived: sum of 2 quarters · filed 2016-05-05 | $444.00K derived: sum of 3 quarters · filed 2016-05-05 | ||
| 2014-12-31 | $36.00K derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-09 | -$19.00K derived: sum of 2 quarters · filed 2016-03-09 | -$2.00K 10-K · filed 2016-03-09 | ||
| 2014-09-30 | -$55.00K derived: 10-Q 9 month − 8-K/A 6 month · filed 2015-11-05 | -$38.00K 10-Q · filed 2015-11-05 | |||
| 2014-06-30 | $17.00K 8-K/A · filed 2015-10-23 | ||||
| 2013-12-31 | -$247.00K 10-K · filed 2016-03-09 | -$246.72K 8-K/A · filed 2015-10-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |